Skip to main content

Table 2 Adverse events (safety population)

From: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

System organ class
Preferred term
Biosimilar ranibizumab (N = 126)
N (%) e
Total events 16 (12.70%) 19
Eye disorder 6 (4.76%) 6
 Corneal edema 1 (0.79%) 1
 Dry eye 1 (0.79%) 1
 Eye pruritus 2 (1.59%) 2
 Iridocyclitis 1 (0.79%) 1
 Ocular hyperaemia 1 (0.79%) 1
General disorders and administration site conditions 6 (4.76%) 6
 Death 1 (0.79%) 1
 Pyrexia 5 (3.97%) 5
Infections and infestations 1 (0.79%) 1
 Nasopharyngitis 1 (0.79%) 1
Investigations 4 (3.17%) 5
 Raised blood pressure 1 (0.79%) 1
 Increase in intraocular pressure 3 (2.38%) 4
Nervous system disorders 1 (0.79%) 1
 Headache 1 (0.79%) 1
  1. N Number of patients, e Number of events
  2. Adverse events were categorized using MedDRA Version 20.1